Viridian Therapeutics, Inc. (NasdaqCM: VRDN)
Health Care · Biotechnology · US
$24.29
+10.01% today · +30.8% 1Y
Viridian Therapeutics, Inc. (NasdaqCM: VRDN) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.75B and employs 252 people.
Over the last twelve months the share price has gained 30.8%, trading between 13.18 and 34.29.
Tweenvest scores Viridian Therapeutics, Inc. across four factors: quality 28/100, value 59/100, growth 70/100. Its strongest factor is growth.
VRDN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.75B
- Revenue (TTM)
- $71.13M
- P/E
- —
- EPS
- -3.46
- Dividend yield
- —
- Beta (5Y)
- 0.94
- 52-week high
- $34.29
- 52-week low
- $13.18
- Avg volume (3M)
- —
- Shares outstanding
- 113.29M
- Employees
- 252
- Next earnings
- —
About Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
- ISIN
- US92790C1045
- Founded
- 2010
- Listed since
- Jun 18, 2014
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.